A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.
Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, Harrington KJ, James ND, Love CA, McNeish I, Medley LC, Michael A, Nutting CM, Pandha HS, Shorrock CA, Simpson J, Steiner J, Steven NM, Wright D, Coombes RC.
Hu JC, et al. Among authors: michael a.
Clin Cancer Res. 2006 Nov 15;12(22):6737-47. doi: 10.1158/1078-0432.CCR-06-0759.
Clin Cancer Res. 2006.
PMID: 17121894
Clinical Trial.